GSK's Dovato wins EU approval; RedHill secures speedy review for H. pylori drug
→ About two months after winning speedy US approval for its dual HIV regimen — Dovato — GSK’s ViiV has secured the European nod. GSK’s $GSK approach to grabbing market share from Gilead $GILD — which currently dominates the HIV market that is estimated to hit $22.5 billion by 2025 — is to convince regulators, doctors and patients to adopt its two-drug regimen, versus Gilead’s triple-drug cocktails, that could potentially result in fewer toxic side-effects, reduce dosing frequency, and be more cost-effective — although critics suggest that this may not be the most effective strategy because the virus will only have to fight against two drugs which could culminate in drug resistance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.